Systems-Level Decoding of Redox Homeostasis in Cancer: From ROS Biology to Therapeutic Vulnerabilities
- 1Beijing Key Laboratory of Environmental and Viral Oncology, College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China
- 2The Department of Clinical Laboratory, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China
Abstract
Reactive oxygen species (ROS) generated during cellular respiration are highly reactive toward proteins, lipids, and DNA. In the context of malignancy, excessive ROS can cause genomic damage, induce mutations, reprogram metabolic pathways, and sustain pro-survival signaling, thereby collectively promoting tumor progression and adaptive fitness. To cope with elevated oxidative stress, tumor cells upregulate antioxidant systems, including the Nrf2–Keap1 axis, the GSH/GPX4 system, and the Trx/TrxR pathway, which collectively maintain ROS within a tolerable range. This redox balance supports malignant growth while simultaneously creating vulnerabilities that may be therapeutically exploited. Current therapeutic strategies can be broadly categorized into two approaches: elevating ROS to levels sufficient to trigger regulated cell death and disrupting redox homeostasis to enhance tumor sensitivity to conventional therapies. However, the spatiotemporal heterogeneity of ROS generation and distribution presents a major challenge to precise therapeutic intervention. Therefore, identifying critical regulatory nodes and establishing robust, quantifiable biomarkers are essential for improving therapeutic precision. Here, we synthesize current knowledge of ROS biology and redox regulation across diverse tumor types, with particular emphasis on therapeutic combinations that integrate redox modulation with metabolic targeting, DNA damage response, and immune activation. Moving forward, quantitative monitoring, systems-level integration, and personalized treatment strategies will be critical for translating redox-based approaches from mechanistic investigation into clinical practice.
Related
- Dynamic perturbation analysis: a modular rewiring framework for decoding cancer stage progression and identifying therapeutic vulnerabilities.
- Decoding cellular vulnerabilities for interpretable drug response prediction
- Integrating transcriptomic analysis to explore biomarkers and therapeutic targets for rheumatoid arthritis: a case-control and systems biology approach.
- Theoretical Considerations Regarding the Role of Hyperinsulinemia and Insulin/IGF Signaling in Cancer Metabolic Reprogramming: Potential Mechanisms and Therapeutic Vulnerabilities
- LGR5-high colorectal cancer defines a Wnt-active stem-like state with multimodal therapeutic vulnerabilities
BibTeX
@article{zhang2026systemslevel,
title = {{Systems-Level Decoding of Redox Homeostasis in Cancer: From ROS Biology to Therapeutic Vulnerabilities}},
author = {Yutian Zhang and Qikang Wang and Lijiao Zhao and Rugang Zhong and Guohui Sun and Ning Lin},
journal = {Molecules},
year = {2026},
month = oct,
doi = {10.3390/molecules31203789},
url = {https://www.mdpi.com/1420-3049/31/20/3789},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Systems-Level Decoding of Redox Homeostasis in Cancer: From ROS Biology to Therapeutic Vulnerabilities
AU - Yutian Zhang
AU - Qikang Wang
AU - Lijiao Zhao
AU - Rugang Zhong
AU - Guohui Sun
AU - Ning Lin
PY - 2026
DA - 2026/10/01
JO - Molecules
DO - 10.3390/molecules31203789
UR - https://www.mdpi.com/1420-3049/31/20/3789
AB - Reactive oxygen species (ROS) generated during cellular respiration are highly reactive toward proteins, lipids, and DNA. In the context of malignancy, excessive ROS can cause genomic damage, induce mutations, reprogram metabolic pathways, and sustain pro-survival signaling, thereby collectively promoting tumor progression and adaptive fitness. To cope with elevated oxidative stress, tumor cells upregulate antioxidant systems, including the Nrf2–Keap1 axis, the GSH/GPX4 system, and the Trx/TrxR pathway, which collectively maintain ROS within a tolerable range. This redox balance supports malignant growth while simultaneously creating vulnerabilities that may be therapeutically exploited. Current therapeutic strategies can be broadly categorized into two approaches: elevating ROS to levels sufficient to trigger regulated cell death and disrupting redox homeostasis to enhance tumor sensitivity to conventional therapies. However, the spatiotemporal heterogeneity of ROS generation and distribution presents a major challenge to precise therapeutic intervention. Therefore, identifying critical regulatory nodes and establishing robust, quantifiable biomarkers are essential for improving therapeutic precision. Here, we synthesize current knowledge of ROS biology and redox regulation across diverse tumor types, with particular emphasis on therapeutic combinations that integrate redox modulation with metabolic targeting, DNA damage response, and immune activation. Moving forward, quantitative monitoring, systems-level integration, and personalized treatment strategies will be critical for translating redox-based approaches from mechanistic investigation into clinical practice.
SN - 1420-3049
ER -